MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.31

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.27

Максимум

1.31

Ключови измерители
By Trading Economics
Приходи	2.7M -24M
EPS	-0.354
Служители	49
EBITDA	-5.3M -28M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+103.82% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-8.4M 73M
Предишно отваряне	1.31
Предишно затваряне	1.31

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.04.2026 г., 17:26 ч. UTC

Значими събития в новините

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7.04.2026 г., 23:55 ч. UTC

Пазарно говорене

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7.04.2026 г., 23:47 ч. UTC

Пазарно говорене

Значими събития в новините

Market Talk Roundup: Latest on U.S. Politics

7.04.2026 г., 23:47 ч. UTC

Пазарно говорене

Значими събития в новините

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7.04.2026 г., 23:44 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7.04.2026 г., 23:42 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

7.04.2026 г., 23:42 ч. UTC

Пазарно говорене

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7.04.2026 г., 23:37 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7.04.2026 г., 23:15 ч. UTC

Пазарно говорене

Значими събития в новините

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7.04.2026 г., 23:04 ч. UTC

Значими събития в новините

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7.04.2026 г., 23:04 ч. UTC

Значими събития в новините

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7.04.2026 г., 23:03 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.04.2026 г., 23:03 ч. UTC

Пазарно говорене

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7.04.2026 г., 23:01 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7.04.2026 г., 22:58 ч. UTC

Значими събития в новините

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7.04.2026 г., 21:56 ч. UTC

Придобивния, сливания и поглъщания

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

7.04.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

7.04.2026 г., 19:45 ч. UTC

Пазарно говорене

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7.04.2026 г., 19:17 ч. UTC

Значими събития в новините

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7.04.2026 г., 19:16 ч. UTC

Пазарно говорене

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7.04.2026 г., 19:07 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

7.04.2026 г., 19:07 ч. UTC

Пазарно говорене

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7.04.2026 г., 18:41 ч. UTC

Придобивния, сливания и поглъщания

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7.04.2026 г., 18:40 ч. UTC

Придобивния, сливания и поглъщания

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7.04.2026 г., 18:39 ч. UTC

Придобивния, сливания и поглъщания

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7.04.2026 г., 18:24 ч. UTC

Значими събития в новините

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7.04.2026 г., 17:08 ч. UTC

Пазарно говорене

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7.04.2026 г., 16:21 ч. UTC

Значими събития в новините

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

103.82% нагоре

12-месечна прогноза

Среден 2.67 USD 103.82%

Висок 3 USD

Нисък 2 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.